Selected Abstracts

Performance evaluation of five detection tests for Avian Influenza antigen with various Avian samples – Study results
Dr Sze-Wee Tan, Rockeby Biomed, Singapore, Singapore

Nuclear and nucleolar targeting of influenza A virus NS1 protein: Striking differences between different virus subtypes
Pr Ilkka Julkunen, Department of Viral Diseases and Immunology National Public Health Institute (KTL), Helsinki, Finland

Sialic acid receptor binding of Influenza haemagglutinin proteins
Dr Holly Shelton, School of Biological Sciences, University of Reading, United Kingdom

Influenza virus inhibitor against wild type and mutant neuraminidase
Dr Jovan Pavlovic, Institute of Medical Virology, University of Zurich, Switzerland

Synergistic inhibition of Avian (H5N1) highly pathogenic influenza virus by POLY I:POLY C12U combined with Oseltamivir or Zanamivir
Dr David Strayer, Hemispherx Biopharma, Inc., Philadelphia, USA

Novel antivirals targeting influenza virus-specific membrane rafts Raft modulating aminosteroids as a new class of anti-influenza compounds
Dr Cornelia Schroeder, Jado Technologies, Dresden, Germany

T cell response to inactivated influenza vaccine in immunocompromised patients
Dr Kathleen E. Sullivan, Chief, Division of Allergy and Immunology, Associate Professor of Pediatrics, The Children's Hospital of Philadelphia, USA

Replication deficient intranasal DEL-NS1 H5N1 influenza vaccine
Dr Julia Romanova, Green Hills Biotechnology AG, Vienna, Austria

Control of avian influenza vaccine potency through oil adjuvant design
Dr Laurent Dupuis, Marketing & Development manager, Vaccine & Injectable Business Unit SEPPIC, Paris La Defense, France

Immunization with Low Dose Adjuvanted Split H5N1 Pandemic Vaccine Protects Ferrets Against Homologous and Heterologous Challenge
Dr Benoit Baras, GlaxoSmithKline Biologicals, Rixensart, Belgium

EFSA scientific opinion on vaccination against avian influenza if H5 and H7 subtypes in domestic poultry and captive birds
Dr Oriol Ribo, Animal Health and Animal Welfare (AHAW) Unit, European Food Safety Authority (EFSA), Parma, Italy

Novel polymer vaccine protects ferrets against lethal challenge with highly pathogenic avian influenza virus
Dr Andrew Cawthon, Battelle Biomedical Research Center, West Jefferson, Ohio, USA

Regional risk assessment for the introduction of avian influenza in poultry production farms
Dr Barbara Grabkowski, Institute for Spacial analysis and Panning in areas of intensive Agriculture (ISPA), University of Vechta, Germany

The spread and evolution of highly pathogenic avian influenza (HPAI) H5N1 in Western Africa
Dr Mariette Ducatez, Institute of Immunology, National PublicHealth Laboratory, Luxembourg

Monitoring of HPAI H5N1 viruses in Russia (2006-2007)
Dr Elena Yudina, Rederal State Research Institution State Research Center of Virology and Biotechnology “VECTOR”, Koltsovo, Russia

Detection of low pathogenic avian influenza virs un wild birds in Catalonia (Spain)
Dr Núria Busquets Martí, Investigadora, Campus de Bellaterra,edifici CReSA, Barcelona, Spain

Avian Influenza tool management
M. Richard Martinez, Project Manager Europe, Middle East & Africa DuPont Chemical Solutions La Défense, France

Pathologic and immunomodulatory effects of a specific nutrient synergy against avian flu virus
Dr Steve Harakeh, Animal Sciences Department, American University of Beirut, Lebanon

Pandemic influenza preparation: cross-reactive immunity with an adjuvanted H5N1 candidate vaccine
Dr Isabel Leroux-Roels, Center of Vaccinology, Ghent University and Hospital GlaxoSmithKline Biological, Ghent, Belgium

Preclinical testing of adjuvanted-H5N1 candidate vaccines
Dr Catherine Caillet, Sanofi Pasteur, Marcy l’Etoile, France

The Romanian family health initiative -avian influenza component
Dr Daniela Pitigoi, JSI Research & Training Institute, INC, Bucharest, Romania

Reduction of the primary atypical pneumonia associated with infection by avian (H5N1) highly pathogenic influenza virus (HPAI) by low dose natural human IFN-a (alferon LDO) administered to the buccal mucosa of cynomolgus macaques
Dr David Strayer, Hemispherx Biopharma, Inc., Philadelphia, USA

Human cases of Avian Flu surveillance in Belgium Dr Carine Gérard, Institute of Public Health – Virology, Brussels, Belgium An improved influenza a vaccine for the elderly
Dr Sarah Abdulla, The Wistar Institute, Philadephia, USA

Elicitation of protective immune responses to pandemic H5N1 Influenza following immunization with A/Indonesia/05/2005 Virus-like particle vaccines
Dr Rick A. Bright, Novavax Inc., Rockville, USA

A new high-yielding and robust production system for vaccine production
Ms Nathalie Landry, Medicago Inc.,Quebec, Canada

Human cases of Avian Flu surveillance in Belgium
Dr Carine Gérard, Institute of Public Health – Virology, Brussels, Belgium

An improved influenza a vaccine for the elderly
Dr Sarah Abdulla, The Wistar Institute, Philadephia, USA

The Romanian family health initiative -avian influenza component
Dr Daniela Pitigoi, JSI Research & Training Institute, INC, Bucharest, Romania

Three approaches to confronting an imminent pandemic
Dr David S. Fedson, Sergy Haut, France